ISSN 1671-5411 CN 11-5329/R

Dear Colleagues,

Journal of Geriatric Cardiology (J Geriatr Cardiol, JGC) will launch a new website and adopt ScholarOne ManuscriptsTM system to manage the submission and peer review process from November 1, 2020. To review and check the status of your manuscripts submitted before November 2020, please visit...

more

Volume 17 Issue 12
Dec.  2020
Turn off MathJax
Article Contents
Si-Qi LYU, Yan-Min YANG, Jun ZHU, Juan WANG, Shuang WU, Jia-Meng REN, Han ZHANG, Xing-Hui SHAO. Effects of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on one-year outcomes of patients with atrial fibrillation: insights from a multicenter registry study in China. J Geriatr Cardiol 2020; 17(12): 750-758. doi: 10.11909/j.issn.1671-5411.2020.12.005
Citation: Si-Qi LYU, Yan-Min YANG, Jun ZHU, Juan WANG, Shuang WU, Jia-Meng REN, Han ZHANG, Xing-Hui SHAO. Effects of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on one-year outcomes of patients with atrial fibrillation: insights from a multicenter registry study in China. J Geriatr Cardiol 2020; 17(12): 750-758. doi: 10.11909/j.issn.1671-5411.2020.12.005

Effects of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on one-year outcomes of patients with atrial fibrillation: insights from a multicenter registry study in China

doi: 10.11909/j.issn.1671-5411.2020.12.005
More Information
  • Corresponding author:

    Yan-Min YANG, Emergency and Critical Care Center, State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. E-mail: yymfuwai@163.com

  • Received Date: 2020-07-01
  • Accepted Date: 2020-11-30
  • Rev Recd Date: 2020-10-12
  • Available Online: 2020-12-28
  • Publish Date: 2020-12-26
  •  Objective To evaluate the effect of angiotensin-converting enzyme inhibitor (ACEI)/angiotensin II receptor blocker (ARB) therapy on the prognosis of patients with atrial fibrillation (AF). Methods A total of 1, 991 AF patients from the AF registry were divided into two groups according to whether they were treated with ACEI/ARB at recruitment. Baseline characteristics were carefully collected and analyzed. Logistic regression was utilized to identify the predictors of ACEI/ARB therapy. The primary endpoint was all-cause mortality, while the secondary endpoints included cardiovascular mortality, stroke and major adverse events (MAEs) during the one-year follow-up period. Univariable and multivariable Cox regression were performed to identify the association between ACEI/ARB therapy and the one-year outcomes. Results In total, 759 AF patients (38.1%) were treated with ACEI/ARB. Compared with AF patients without ACEI/ARB therapy, patients treated with ACEI/ARB tended to be older and had a higher rate of permanent AF, hypertension, diabetes mellitus, heart failure (HF), left ventricular ejection fraction (LVEF) < 40%, coronary artery disease (CAD), prior myocardial infarction (MI), left ventricular hypertrophy, tobacco use and concomitant medications (all P < 0.05). Hypertension, HF, LVEF < 40%, CAD, prior MI and tobacco use were determined to be predictors of ACEI/ARB treatment. Multivariable analysis showed that ACEI/ARB therapy was associated with a significantly lower risk of one-year all-cause mortality [hazard ratio (HR) (95% CI): 0.682 (0.527-0.882), P = 0.003], cardiovascular mortality [HR (95% CI): 0.713 (0.514-0.988), P = 0.042] and MAEs [HR (95% CI): 0.698 (0.568-0.859), P = 0.001]. The association between ACEI/ARB therapy and reduced mortality was consistent in the subgroup analysis. Conclusions In patients with AF, ACEI/ARB was related to significantly reduced one-year all-cause mortality, cardiovascular mortality and MAEs despite the high burden of cardiovascular comorbidities.
  • loading
  • [1]
    Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation 2014; 129: 837-847. doi: 10.1161/CIRCULATIONAHA.113.005119
    [2]
    January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2014; 64: e1-e76. doi: 10.1016/j.jacc.2014.03.022
    [3]
    Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace 2016; 18: 1609-1678. doi: 10.1093/europace/euw295
    [4]
    Kim M, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011; 4: 313-320. doi: 10.1161/CIRCOUTCOMES.110.958165
    [5]
    Ball J, Carrington MJ, McMurray JJ, et al. Atrial fibrillation: profile and burden of an evolving epidemic in the 21st century. Int J Cardiol 2013; 167: 1807-1824. doi: 10.1016/j.ijcard.2012.12.093
    [6]
    Schnabel RB, Yin X, Gona P, et al. 50 year trends in atrial fibrillation prevalence, incidence, risk factors, and mortality in the Framingham Heart Study: a cohort study. Lancet 2015; 386: 154-162. doi: 10.1016/S0140-6736(14)61774-8
    [7]
    Vermond RA, Geelhoed B, Verweij N, et al. Incidence of atrial fibrillation and relationship with cardiovascular events, heart failure, and mortality: a community-based study from the Netherlands. J Am Coll Cardiol 2015; 66: 1000-1007. doi: 10.1016/j.jacc.2015.06.1314
    [8]
    Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: the Framingham Heart Study. Circulation 2003; 107: 2920-2925. doi: 10.1161/01.CIR.0000072767.89944.6E
    [9]
    Savelieva I, Kakouros N, Kourliouros A, et al. Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part Ⅱ: secondary prevention. Europace 2011; 13: 610-625. doi: 10.1093/europace/eur023
    [10]
    Lei M, Wu L, Terrar DA, et al. Modernized classification of cardiac antiarrhythmic drugs. Circulation 2018; 138: 1879-1896. doi: 10.1161/CIRCULATIONAHA.118.035455
    [11]
    Iwasaki YK, Nishida K, Kato T, et al. Atrial fibrillation pathophysiology: implications for management. Circulation 2011; 124: 2264-2274. doi: 10.1161/CIRCULATIONAHA.111.019893
    [12]
    Nattel S, Burstein B, Dobrev D. Atrial remodeling and atrial fibrillation: mechanisms and implications. Circ Arrhythm Electrophysiol 2008; 1: 62-73. doi: 10.1161/CIRCEP.107.754564
    [13]
    Moreno I, Caballero R, González T, et al. Effects of irbesartan on cloned potassium channels involved in human cardiac repolarization. J Pharmacol Exp Ther 2003; 304: 862-873. doi: 10.1124/jpet.102.042325
    [14]
    Shi Y, Li D, Tardif JC, et al. Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 2002; 54: 456-461. doi: 10.1016/S0008-6363(02)00243-2
    [15]
    Schneider MP, Hua TA, Böhm M, et al. Prevention of atrial fibrillation by renin-angiotensin system inhibition a meta-analysis. J Am Coll Cardiol 2010; 55: 2299-2307. doi: 10.1016/j.jacc.2010.01.043
    [16]
    Yamashita T, Inoue H, Okumura K, et al. Randomized trial of angiotensin Ⅱ-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM Ⅱ Study). Europace 2011; 13: 473-479. doi: 10.1093/europace/euq439
    [17]
    Disertori M, Latini R, Barlera S, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360: 1606-1617. doi: 10.1056/NEJMoa0805710
    [18]
    Schmieder RE, Kjeldsen SE, Julius S, et al. Reduced incidence of new-onset atrial fibrillation with angiotensin Ⅱ receptor blockade: the VALUE trial. J Hypertens 2008; 26: 403-411. doi: 10.1097/HJH.0b013e3282f35c67
    [19]
    Wachtell K, Hornestam B, Lehto M, et al. Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 705-711. doi: 10.1016/j.jacc.2004.06.080
    [20]
    Lip GY, Frison L, Grind M. Angiotensin converting enzyme inhibitor and angiotensin receptor blockade use in relation to outcomes in anticoagulated patients with atrial fibrillation. J Intern Med 2007; 261: 577-586. doi: 10.1111/j.1365-2796.2007.01780.x
    [21]
    Yusuf S, Healey JS, Pogue J, et al. Irbesartan in patients with atrial fibrillation. New Engl J Med 2011; 364: 928-938. doi: 10.1056/NEJMoa1008816
    [22]
    Arima H, Hart RG, Colman S, et al. Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack. Stroke 2005; 36: 2164-2169. doi: 10.1161/01.STR.0000181115.59173.42
    [23]
    Du X, Ninomiya T, de Galan B, et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J 2009; 30: 1128-1135. doi: 10.1093/eurheartj/ehp055
    [24]
    Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006; 47: 1997-2004. doi: 10.1016/j.jacc.2006.01.060
    [25]
    Friberg L, Benson L, Lip GY. Balancing stroke and bleeding risks in patients with atrial fibrillation and renal failure: the Swedish Atrial Fibrillation Cohort study. Eur Heart J 2015; 36: 297-306. doi: 10.1093/eurheartj/ehu139
    [26]
    Nabauer M, Gerth A, Limbourg T, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace 2009; 11: 423-434.
    [27]
    Nielsen PB, Larsen TB, Skjøth F, et al. Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation 2015; 132: 517-525. doi: 10.1161/CIRCULATIONAHA.115.015735
    [28]
    Olesen JB, Lip GY, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011; 342: d124. doi: 10.1136/bmj.d124
    [29]
    Oldgren J, Healey JS, Ezekowitz M, et al. Variations in cause and management of atrial fibrillation in a prospective registry of 15, 400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. Circulation 2014; 129: 1568-1576. doi: 10.1161/CIRCULATIONAHA.113.005451
    [30]
    Liang HF, Du X, Zhou YC, et al. Control of anticoagulation therapy in patients with atrial fibrillation treated with warfarin: a study from the Chinese Atrial Fibrillation Registry. Med Sci Monit 2019; 25: 4691-4698. doi: 10.12659/MSM.917131
    [31]
    Ducharme A, Swedberg K, Pfeffer MA, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 152: 86-92. doi: 10.1016/j.ahj.2005.06.036
    [32]
    Braunwald E, Domanski MJ, Fowler SE, et al. Angiotensin- converting-enzyme inhibition in stable coronary artery disease. N Engl J Med 2004; 351: 2058-2068. doi: 10.1056/NEJMoa042739
    [33]
    McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. New Engl J Med 2010; 362: 1477-1490. doi: 10.1056/NEJMoa1001121
    [34]
    Sleight P, Redon J, Verdecchia P, et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens 2009; 27: 1360-1369. doi: 10.1097/HJH.0b013e32832d7370
    [35]
    Cohn JN, Tognoni G, Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667-1675. doi: 10.1056/NEJMoa010713
    [36]
    Yusuf S, Diener HC, Sacco RL, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008; 359: 1225-1237. doi: 10.1056/NEJMoa0804593
    [37]
    Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893-1906. doi: 10.1056/NEJMoa032292
    [38]
    Côté N, Mahmut A, Fournier D, et al. Angiotensin receptor blockers are associated with reduced fibrosis and interleukin-6 expression in calcific aortic valve disease. Pathobiology 2014; 81: 15-24. doi: 10.1159/000350896
    [39]
    Chen YJ, Chen YC, Tai CT, et al. Angiotensin Ⅱ and angiotensin Ⅱ receptor blocker modulate the arrhythmogenic activity of pulmonary veins. Br J Pharmacol 2006; 147: 12-22. doi: 10.1038/sj.bjp.0706445
    [40]
    von Lewinski D, Kockskämper J, Rübertus SU, et al. Direct pro-arrhythmogenic effects of angiotensin Ⅱ can be suppressed by AT1 receptor blockade in human atrial myocardium. Eur J Heart Fail 2008; 10: 1172-1176. doi: 10.1016/j.ejheart.2008.09.014
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(3)

    Article Metrics

    Article views (94) PDF downloads(8) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return